Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

37.00 -0.44 (-1.18%) As of 11:29AM CST. Market open.

Jiangsu Hengrui Medicine Co., Ltd.

38 Huanghe Rd Eco & Tech Dev Park
Lianyungang 222000
China
86 518 8122 0983
https://www.hrs.com.cn

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 24,491

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jianjun Liu	Financial Director	N/A	N/A	1978
Ms. Su Mei Jiang	Exec. Deputy GM & Director	N/A	N/A	1965
Mr. Jie Ping Sun	Deputy GM & Director	N/A	N/A	1970
Mr. Hong Bin Dai	Deputy GM & Director	N/A	N/A	1976
Dr. Lian Shan Zhang Ph.D.	Deputy GM & Director	N/A	N/A	1962
Mr. Kai Hong Yuan	Deputy Gen. Mang.	N/A	N/A	1965
Mr. Ya Ping Shen	Deputy Gen. Mang.	N/A	N/A	1964
Mr. Xu Gen Sun	Deputy Gen. Mang.	N/A	N/A	1970
Mr. Wei Kang Tao	Deputy Gen. Mang.	N/A	N/A	1964
Mr. Cheng Liao	Deputy Gen. Mang.	N/A	N/A	1975

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Corporate Governance

Jiangsu Hengrui Medicine Co., Ltd.’s ISS Governance QualityScore as of July 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.